Volastra Therapeutics

Volastra Therapeutics, Inc. is a clinical stage oncology biotechnology company based in New York City. Founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento, Volastra is focused on developing therapeutics that exploit chromosomal instability (CIN) as a unique vulnerability in cancer. The company has grown since its founding in 2019 and now supports ongoing discovery efforts as well as a growing clinical organization.

Volastra most advanced pipeline medicines are 2 distinct inhibitors of KIF18A, a novel therapeutic target. The first medicine, VLS-1488 was internally discovered and is currently in Phase I for the treatment of advanced cancers. The second KIF18A inhibitor is sovilnesib, a clinical stage KIF18A inhibitor licensed from Amgen in February 2023 and for which the company is in the process of initiating a Phase 1b trial in Q1 2024.

Volastra is financed by top US and European venture firms, including Arch Ventures, Polaris Partners, Vida Venture, Droia Ventures, Catalio Capital as well as from strategic investor Eli Lilly. In addition to venture funding, Volastra has a multi-year drug discovery collaboration with Bristol Myers Squibb and a biomarker discovery partnership with Microsoft to use artificial intelligence to measure chromosomal instability. The company has a highly experienced senior leadership team and a world class advisory board.

The company operates out of office and laboratory space in West Harlem, New York City, within easy traveling distance of most areas of the city, Westchester County, and New Jersey. Please visit www.volastratx.com for more information.